somatostatin analogue
Octreotide dose
Answer
FDA label for Mycapssa: Recommended dosage is 80 mg daily ( 2.2 ). Half-life on the label: 1.7 to 1.9 hours. Trials with posted results tested 5 doses, most often 60 mg, 40 mg, 30 mg.
Not dosing advice.
FDA LABEL
What the approved labels state
Sandostatin NDA019667 · label of 2026-07-22 Regulator
Half-life: 1.7 to 1.9 hours (section 12.3).
Octreotide Acetate ANDA216839 · label of 2026-01-30 Regulator
Half-life: 1.7 to 1.9 hours (section 12.3).
Sandostatin LAR Depot NDA021008 · label of 2025-12-22 Regulator
Half-life: 1.7 hours (section 12.3).
Mycapssa NDA208232 · label of 2025-07-24 Regulator
Recommended dosage is 80 mg daily ( 2.2 ).
The maximum recommended dosage is 80 mg daily ( 2.2 ).
IN TRIALS
Doses tested in 67 trials with posted results
| Dose in the arm title | Trials | People on it | Phases |
|---|---|---|---|
| 60 mg | 2 | 164 | 3 |
| 40 mg | 1 | 155 | 3 |
| 30 mg | 1 | 147 | 3 |
| 80 mg | 1 | 58 | 3 |
| 300 mcg | 1 | 20 | 2 |
Trial register Read from the titles of arms that received Octreotide (n ≥ 20). An arm naming several doses counts under each; a schedule or escalation is on the trial record. All trials.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.